As Flexion Therapeutics INC (FLXN) Market Valuation Declined, Clearline Capital LP Has Raised Position by $4.25 Million

Flexion Therapeutics, Inc. (NASDAQ:FLXN) LogoInvestors sentiment is 1.49 in 2019 Q2. Its the same as in 2019Q1. It is the same, as 15 investors sold FLXN shares while 24 reduced holdings. only 16 funds opened positions while 42 raised stakes. 30.64 million shares or 5.82% less from 32.53 million shares in 2019Q1 were reported. Mark Sheptoff Fincl Planning Limited Liability Corporation reported 700 shares stake. Moreover, Raymond James And Assoc has 0% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 220,899 shares. Invesco Limited holds 0% or 109,240 shares. Vanguard Group reported 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Schroder Investment Gp invested in 0.01% or 568,876 shares. Ubs Asset Management Americas holds 0% or 10,158 shares in its portfolio. Goldman Sachs Gru Incorporated reported 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). Fin Architects Incorporated has 0% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 400 shares. Cap Ww Investors holds 2.51M shares. California Public Employees Retirement holds 46,600 shares or 0% of its portfolio. Glenmede Co Na holds 888 shares. Voya Investment Mgmt Llc accumulated 14,280 shares. Bnp Paribas Arbitrage holds 3,759 shares. Amer Century Inc owns 168,472 shares for 0% of their portfolio. Citigroup has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Since May 23, 2019, it had 4 insider purchases, and 0 insider sales for $175,363 activity. Shares for $21,480 were bought by COLELLA SAMUEL D on Thursday, August 8. 2,500 Flexion Therapeutics, Inc. (NASDAQ:FLXN) shares with value of $27,627 were bought by Arkowitz David. The insider Clayman Michael D. bought 2,317 shares worth $25,136.

Clearline Capital Lp increased its stake in Flexion Therapeutics Inc (FLXN) by 63.56% based on its latest 2019Q2 regulatory filing with the SEC. Clearline Capital Lp bought 353,832 shares as the company’s stock declined 3.46% . The hedge fund held 910,542 shares of the health care company at the end of 2019Q2, valued at $11.20 million, up from 556,710 at the end of the previous reported quarter. Clearline Capital Lp who had been investing in Flexion Therapeutics Inc for a number of months, seems to be bullish on the $533.11 million market cap company. The stock decreased 0.99% or $0.14 during the last trading session, reaching $13.99. About 561,982 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has declined 56.61% since September 13, 2018 and is downtrending. It has underperformed by 56.61% the S&P500.

More notable recent Flexion Therapeutics, Inc. (NASDAQ:FLXN) news were published by: Seekingalpha.com which released: “Flexion Therapeutics: A Second (And More) Life For Zilretta – Seeking Alpha” on April 23, 2019, also Nasdaq.com with their article: “Flexion Therapeutics to Present at the Wells Fargo Securities 2019 Healthcare Conference – Nasdaq” published on August 28, 2019, Seekingalpha.com published: “Flexion down 13% on departure of commercial chief – Seeking Alpha” on April 10, 2019. More interesting news about Flexion Therapeutics, Inc. (NASDAQ:FLXN) were released by: Seekingalpha.com and their article: “Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook – Seeking Alpha” published on January 03, 2019 as well as Seekingalpha.com‘s news article titled: “Flexion Therapeutics: The Bottom Could Now Be In – Seeking Alpha” with publication date: May 15, 2019.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.